Successes are held regularly in the field of cancer genetics. But if patients are not screened and are not diagnosed early enough, progress can not save lives. Presentation at the Annual Meeting of the Society of North America on menopause (NAMS) in San Diego, October 3-6, will consider various options for genetic testing for breast cancer, as well as the profiles of those who should be tested.
It is estimated that 12-14% of breast cancers are associated with inherited predisposition to cancer syndromes. This means that almost 35,000 cases of breast cancer are hereditary risk every year. When breast cancer is detected early enough, women have much better chances of survival. These chances are increased if the likelihood of breast cancer can be reduced by the use of different preventive medications and surgical procedures that reduce the risk.
In his speech at the upcoming Annual Meeting of NAMS Dr. Holly Pederson from the Cleveland Clinic to provide convincing evidence, designed to encourage health care providers to be more proactive in identifying patients most at risk, as well as recommendations for genetic counseling and testing. She will discuss the various developments in the field of genetic testing, including testing of multi panels, which will be more efficient and economical, as well as discuss the new SNP panel and the pros and cons that are directly related to consumer tests.
"It is imperative that we identified patients with hereditary predisposition to breast cancer as early as possible", - says Dr. Pederson. "If patients are concerned about the cost of genetic testing, they can be sure that the law on the protection of patients and accessible health care identifies BRCA testing as a preventive service. Medicare provides coverage of affected patients qualified personal history, and 97% of commercial insurers and most state Medicaid programs provide coverage for hereditary testing for cancer. "
"Health care providers need to understand the importance of early screening and advances in cancer genetics, allowing you to save lives," - says Dr. Joanne Pinkerton, executive director of NAMS.